GloMax® Galaxy Bioluminescence Imager: Transforming Protein Dynamics Research 12/12/2024 Healthcare Innovative drugs Promega has launched the GloMax® Galaxy Bioluminescence Imager, an innovative tool for visualizing protein dynamics in... Partners - Promega
Polypharmacology as the Future of Drug Design 22/11/2024 Healthcare Innovative drugs Partners - Nostrum Biodiscovery
Gate2Brain Receives EMA Orphan Drug Designation for Its Groundbreaking Pediatric Cancer T... 19/11/2024 Healthcare Innovative drugs Partners - Gate2Brain
#GreenInnovationForum | “To move toward net-zero emissions in healthcare, at AstraZeneca w... 12/11/2024 Healthcare Innovative drugs International We interviewed Marta Moreno, Director of Corporate Affairs and Market Access at AstraZeneca Spain, Bronze Sponsor of the... AseBio
The Fight Against Pneumonia and Antibiotic Resistance: Vaxdyn and the K-Vax Vaccine Candid... 11/11/2024 Healthcare Access to innovation Innovative drugs On the occasion of World Pneumonia Day, we interviewed Juanjo Infante, CEO of Vaxdyn, a biotech company developing the K... Partners
Access to Innovative Therapies in Spain: Challenges and Opportunities 07/11/2024 Healthcare Access to innovation Innovative drugs Advanced therapies International In this article, Chus Castillo, Partner Consulting Iberia at Alira Health, and Ion Arocena, General Manager at AseBio... Partners - Alira Health
AI in Drug Developement: Transforming Drug Discovery and Repurposing Online Del 22/11/2024 11:00 to 22/11/2024 Healthcare Innovative drugs Communication
INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer In... 29/10/2024 Healthcare Access to innovation Innovative drugs VC funding led by imec.xpand, with significant participation from the EIC Fund (venture arm of the European Innovation... Partners - Asabys Partners
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European ... 23/10/2024 Healthcare Access to innovation Innovative drugs Partners - THERIVA BIOLOGICS S.L.
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic ... 18/10/2024 Healthcare Innovative drugs ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1 Partners - ARTHEx Biotech
